MARY KATHRYN CHESTANG: Open Payments
NPI 1205463338 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,496 in 115 payments from 21 companies in 2025. Trend: 2023 $1,929 · 2024 $2,252 · 2025 $2,496
Food & beverage: $2,496
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $353 |
| Mallinckrodt Hospital Products Inc. | 12 | $260 |
| GENZYME CORPORATION | 10 | $236 |
| Amgen Inc. | 15 | $225 |
| AstraZeneca Pharmaceuticals LP | 9 | $203 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $168 |
| Philips North America LLC | 8 | $149 |
| Grifols USA, LLC | 5 | $124 |
| Merck Sharp & Dohme LLC | 6 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $90 |
Products named: TEZSPIRE, DUPIXENT, ACTHAR, TRELEGY ELLIPTA, NUCALA, Vest Therapy Und, Prolastin-C Liquid, ZERBAXA.
Industry payments across AL — which companies pay providers there.
